The short version of circadian clock fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
The upper part of trachea receives and drains blood through the inferior thyroid arteries and veins; the lower trachea receives blood from bronchial arteries. Arteries that supply the trachea do so via small branches that supply the trachea from the sides. As the branches approach the wall of the trachea, they split into inferior and superior branches, which join with the branches of the arteries above and below; these then split into branches that supply the anterior and posterior parts of the trachea. The inferior thyroid arteries arise just below the isthmus of the thyroid, which sits atop the trachea. These arteries join (anastamoses) with ascending branches of the bronchial arteries, which are direct branches from the aorta, to supply blood to the trachea. The lymphatic vessels of the trachea drain into the pretracheal nodes that lie in front of the trachea, and paratracheal lymph nodes that lie beside it.
=== Cost effectiveness === The costs of methenamine for long-term UTI prophylaxis can be significant. However, a 2024 study found that methenamine was more cost-effective than low-dose prophylactic antibiotics for prevention of UTIs.
==== Harris lines ==== Harris lines form before adulthood, when bone growth is temporarily halted or slowed down due to some sort of stress (typically disease or malnutrition). During this time, bone mineralization continues, but growth does not, or does so at reduced levels. If and when the stressor is overcome, bone growth resumes, resulting in a line of increased mineral density visible in a radiograph. Absent removal of the stressor, no line forms. Particularly, deficiencies in protein and vitamins, which lead to delayed longitudinal bone growth, can result in the formation of Harris lines. During the process of endochondral bone growth, the cessation of osteoblastic activity results in the deposition of a thin layer of bone beneath the cartilage cap, potentially forming Harris lines. Subsequent recovery, necessary for the restoration of osteoblastic activity, is also implicated in Harris line formation. When matured cartilage cells reactivate, bone growth resumes, thickening the bony stratum. Therefore, complete recovery from periods of chronic illness or malnutrition manifests as transverse lines on radiographs. Lines tend to be thicker with prolonged and severe malnutrition. Harris line formation typically peaks in long bones around 2–3 years after birth and becomes rare after the age of 5 until adulthood. Harris lines occur more frequently in boys than in girls.
Sources: en.wikipedia.org
=== Ideology === Will Lavin wrote for Complex in late 2025 that Peters was "often deemed controversial" online. Williams of The Atlantic wrote that Peters's "brand of nihilism" was enticing to young men and in February 2026, Chloe Combi described Peters as having attracted "a huge and growing Gen A boy following". For Intelligencer, Ezra Marcus described Peters as "something of an edgelord folk hero" whose "profit strategy fuses shock-jock tactics with straightforward marketing". Charlie Sabgir, director of the Young Men Research Project, wrote in January 2026 for Rolling Stone, "His fixation on optimization is inseparable from aggressive sexism." Looksmaxxing in general, and Clavicular specifically, have been criticized as likely to harm impressionable young men by promoting unrealistic beauty standards and exposing them to incel ideology and misogynistic rhetoric. A March 2026 column in The Guardian compared Clavicular's "self improvement" methods to body dysmorphia. For Wired, Jason Parham wrote in September 2025 that Peters was one of looksmaxxing's "most popular influencers". In January 2026, Thomas Chatterton Williams of The Atlantic referred to him as the "newest star" and "most recognizable member" of the looksmaxxing movement, Charlie Sabgir of Rolling Stone called him "a premier figure" within looksmaxxing, and Dave Schilling of The Guardian called him "one of the most prominent influencers in the looksmaxxing community".
Silent mutations affect protein folding and function. Normally a misfolded protein can be refolded with the help of molecular chaperones. RNA typically produces two common misfolded proteins by tending to fold together and become stuck in different conformations and it has a difficulty singling in on the favored specific tertiary structure because of other competing structures. RNA-binding proteins can assist RNA folding problems, however, when a silent mutation occurs in the mRNA chain, these chaperones do not bind properly to the molecule and are unable to redirect the mRNA into the correct fold. Recent research suggests that silent mutations can have an effect on subsequent protein structure and activity. The timing and rate of protein folding can be altered, which can lead to functional impairments.
== Corporate structure == In the financial year 2023, Basilea Pharmaceutica AG, Allschwil generated company sales of CHF 157.6 million and employed 147 people. Since the 2022 financial year, Basilea has consistently been generating operating and net profits. In addition to its headquarters in Allschwil, Switzerland, Basilea is represented by subsidiaries in the UK and Germany. Basilea cooperates with licence and distribution partners in over 100 countries.
Sources: en.wikipedia.org
The option of 3D printing items in space holds many advantages over manufacturing situated on Earth. With 3D printing technologies, rather than exporting tools and equipment from Earth into space, astronauts have the option to manufacture needed items directly. On-demand patterns of manufacturing make long-distance space travel more feasible and self-sufficient as space excursions require less cargo. Mission safety is also improved. The Made In Space, Inc. 3D printers, which launched in 2014 to the International Space Station, are designed specifically for a zero-gravity or micro-gravity environment. The effort was awarded the Phase III Small Business Innovation and Research Contract. The Additive Manufacturing Facility will be used by NASA to carry out repairs (including during emergency situations), upgrades, and installation. Made In Space lists the advantages of 3D printing as easy customization, minimal raw material waste, optimized parts, faster production time, integrated electronics, limited human interaction, and option to modify the printing process. The Refabricator experiment, under development by Firmamentum, a division of Tethers Unlimited, Inc. under a NASA Phase III Small Business Innovation Research contract, combines a recycling system and a 3D printer to perform demonstration of closed-cycle in-space manufacturing on the International Space Station (ISS).
=== Health care === Wittman opposes the Affordable Care Act and has voted to repeal it. He said that Congress should not merely be "anti-Obamacare" and that congressional Republicans are ready to provide alternatives if it is deemed unconstitutional. In 2017, he voted for the American Health Care Act, which would have repealed and replaced the ACA.
The unidirectionality of the system is a result from both the asymmetric skew of the helicene moiety as well as the strain of the cyclic urethane which is formed in c. This strain can be only be lowered by the clockwise rotation of the triptycene rotor in d, as both counterclockwise rotation as well as the inverse process of d are energetically unfavorable. In this respect the preference for the rotation direction is determined by both the positions of the functional groups and the shape of the helicene and is thus built into the design of the molecule instead of dictated by external factors.
Small humanin-like peptides (SHLPs) are a group of peptides encoded in the 16S ribosomal RNA region of mitochondrial genome. Six peptides of this group (SHLP1–6) have been identified so far, between 20-38 amino acids in length. They are derived from the mitochondria and act as important retrograde signaling molecules in the cell. Their names were given because the SHLPs share some similar biological effects with the mitochondrial peptide Humanin. Every individual SHLP showed unique expression pattern in mouse tissues. Specifically, SHLP1 was detected in the heart, kidney, and spleen; SHLP2 was detected in the liver, kidney, and muscle; SHLP3 was detected in the brain and spleen; SHLP4 was detected in the liver and prostate; and SHLP6 was detected in the liver and kidney. Experiments using cultured mammalian cells have shown that SHLPs are bioactive peptides. Incubation of each synthetic SHLP with cells affected cell viability, proliferation and apoptosis differentially, which suggests that every SHLP may play a different role in the biological system.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.